TY - JOUR T1 - The <em>Plasmodium falciparum</em> Drugome And Its Polypharmacological Implications JF - bioRxiv DO - 10.1101/042481 SP - 042481 AU - Yinliang Zhang AU - Li Xie AU - Lei Xie AU - Philip E. Bourne Y1 - 2016/01/01 UR - http://biorxiv.org/content/early/2016/03/05/042481.abstract N2 - Malaria is a disease contracted by over 200 million people each year, mostly in developing countries. The primary causative agent, Plasmodium falciparum (P. falciparum) has shown increased resistance to existing drugs, hence new treatments are needed quickly. To this end we performed a high-throughput systems-level analysis, mapping existing FDA drugs with the potential for repurposing against targets from the P. falciparum structural proteome. The resulting P. falciparum drugome (P.falciparum-drugome) was used to prioritize potential new anti-malaria candidate targets and highlight some novel FDA approved drugs that have apparent anti-malaria effects for possible use as multi-target therapeutics. ER -